Capricor Therapeutics(NASDAQ) CAPR

Capricor makes medicines to help people with rare and life-threatening muscle diseases. Its main treatments help young patients whose muscles and hearts are getting weaker. The company uses specialized donor cells to deliver healing signals to the body.

What is Capricor Developing?

• Deramiocel: Cell therapy using donor heart cells to treat muscle and heart decline in Duchenne muscular dystrophy, a rare genetic disease.
• StealthX Platform: Technology that uses tiny natural bubbles called exosomes to deliver medicine and vaccines directly to cells.
• SARS-CoV-2 Vaccine: Experimental vaccine designed to protect against COVID-19 using the company's exosome delivery system.
• Becker Muscular Dystrophy: Research program focused on using cell therapy to help patients with a slower-progressing form of genetic muscle disease.

Strategic Partners and Growth

• Partnered with Nippon Shinyaku in 2022 for the exclusive distribution of its lead therapy in the United States.
• Expanded the Nippon Shinyaku agreement in 2023 to include exclusive distribution rights for the Japanese market.
• Joined Project NextGen in 2023, a federal program with the NIH, to test new and innovative vaccine technologies.
• Signed a binding term sheet with Nippon Shinyaku in 2024 to potentially bring its lead product to the European region.
• Licensed specialized cell line technology from Life Technologies Corporation in 2022 to support its exosome research and development.

Inside the Operations

Capricor operates a primary manufacturing site in San Diego, which was recently expanded by 22,000 square feet to prepare for commercial production. The company holds exclusive rights to its core technologies through long-term licenses with Cedars-Sinai Medical Center and Johns Hopkins University.

Key Financial Figures

• Revenue was $0 in Q4 2025, down 100% from $11.1 million in Q4 2024.
• Net income was negative $30.2 million in Q4 2025, down 324% year-over-year.
• Free cash flow reached negative $28.7 million in Q4 2025, down 84.7% from the previous year.
• Market capitalization hit $1.4 billion in Q4 2025, up 190.1% year-over-year.
• Operating cash flow was negative $23.6 million in Q4 2025, down 59.3% from Q4 2024.

Bottom Line

Capricor has transitioned from early research into a company now seeking final approval for its first commercial product. Its focus on specialized cell therapies and exosome delivery systems positions it to address rare diseases with few existing treatment options.